Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients

This study looks for biological markers in bone marrow and blood that could help identify or predict acute myeloid leukemia (AML, a blood cancer) in older patients, by comparing samples from AML patients with those from older adults having heart surgery (who do not have leukemia). **You may be eligible if...** - You are 60 years old or older - AML group: You have been newly diagnosed with AML and are scheduled to receive treatment with azacitidine - Control group: You are scheduled for heart surgery involving a sternotomy and have a normal recent blood count - You are able to provide written informed consent **You may NOT be eligible if...** - You have a blood disorder other than AML (AML group) - You have signs of leukemia in the central nervous system or only outside the bone marrow - You have previously been treated for AML (other than with hydroxyurea) - You have active HIV, hepatitis B, or hepatitis C - You have severe conditions that would interfere with the study - You are under legal protection or deprived of liberty Talk to your doctor to see if this trial is right for you.